A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma.
Blass E, Keskin DB, Tu CR, Forman C, Vanasse A, Sax HE, Shim B, Chea V, Kim N, Carulli I, Southard J, Lyu H, Lu W, Rickles-Young M, Afeyan AB, Olive O, Mehndiratta A, Greenslade H, Shetty K, Baginska J, Gomez Diaz I, Nau A, Pfaff KL, Gans A, Ranasinghe S, Buchbinder EI, Sussman TA, Insco ML, Yoon CH, Rodig SJ, Shukla SA, Li S, Aster JC, Braun DA, Cibulskis C, Hacohen N, Neuberg DS, Giobbie-Hurder A, Livak KJ, Fritsch EF, Oliveira G, Simon JM, Wu CJ, Ott PA.
Blass E, et al. Among authors: nau a.
Cell. 2025 Sep 18;188(19):5125-5141.e27. doi: 10.1016/j.cell.2025.06.019. Epub 2025 Jul 10.
Cell. 2025.
PMID: 40645179
Clinical Trial.